Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis
Abstract Background Prevalence of hepatitis C virus (HCV) infection among people who inject drugs (PWID) in Iran is high. Since 2005, the Iranian government has implemented a harm reduction program to control HCV. We aimed to describe the prevalence of HCV antibody (Ab) in Iranian PWID before and af...
Saved in:
Main Authors: | Abdolhalim Rajabi (Author), Heidar Sharafi (Author), Seyed Moayed Alavian (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
P27 Hepatitis B outreach to people who inject drugs (PWID)
by: L. Kanaef
Published: (2017) -
Access to free DAAs for people who inject drugs: is it sufficient to increase the update of HCV treatment by PWIDs?
by: Maka Gogia, et al.
Published: (2018) -
Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
by: Heidar Sharafi, et al.
Published: (2020) -
Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies
by: Meisam Moghimbeygi, et al.
Published: (2020) -
People who inject drugs (PWID) and HIV/aids cases in Mexico City: 1987-2015
by: Martha Romero Mendoza, et al.
Published: (2019)